雅本化學(300261.SZ)：信批違法被責令整改並遭罰40萬元
格隆匯 9 月 9日丨雅本化學(300261.SZ)公佈，2020年9月9日，公司收到中國證券監督管理委員會下發的《行政處罰決定書》([2020]59號)。
2020年2月3日、2月4日，雅本化學在深交所投資者關係互動平台對投資者關於“公司是否生產用於肺炎疫情相關抗病毒藥物的醫藥中間體”等提問回覆中表示，子公司樸頤化學是抗病毒藥阿扎那韋及達蘆那韋關鍵中間體的主要供應商。
事實上，雅本化學2017年至2019年銷售或提供達蘆那韋醫藥中間體產品和服務取得的收入金額為245.69萬元、483.76萬元、506.13萬元，其中樸頤化學和其控股子公司湖州頤輝生物科技有限公司(以下簡稱頤輝生物)的收入金額分劃為111.22萬元、351.76萬元和506.13萬元，較《關注函回覆》披露金額分別少2947.96萬元、4944.58萬元和2687.63萬元。雅本化學披露的上述銷售收入將下游客户江蘇八巨藥業有限公司銷售的氯醇和BOC環氧物等達盧那韋醫藥中間體統計成自己的收入。
雅本化學、樸頤化學和頤輝生物未與印度客户Emucure、Mylan、Cipla、Sun、Laures以及國內客户迪賽諾直接簽署業務合同和供貨，只是根據樸頤化學與八巨藥業簽訂的《技術服務和客户保護協議》，由樸頤化學獨家負責與上述客户的談判、報價和成交，八巨藥業按照與上述客户銷售金額的一定比例向樸頤化學支付佣金。雅本化學披露的上述產品的銷量、產能及利用率，是根據八巨藥業的產能和訂單情況估計並倒算出各年度銷量。
雅本化學上述信息披露未能客觀、準確、完整地反映涉及達蘆那韋醫藥中間體業務的實際情況，誇大了公司該業務的收入、產量、銷量和市場地位，具有較大誤導性。
證監會認為，雅本化學的上述行為違反了2005年《證券法》第六十三條的規定，構成2005年《證券法》第一百九十三條第一款所述的信息披露違法行為。因此，證監會決定：一、對雅本化學股份有限公司責令改正，給予警告，並處以40萬元罰款；二、對時任董事長、總經理蔡彤給予警告，並處以20萬元罰款；三、對時任董事、董事會祕書王卓穎、公司時任董事、樸頤化學總經理王博給予警告，並分別處以15萬元罰款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
